Pacira (PCRX) Remains Rare 'Hyper Growth' Story - Jefferies

Jefferies analyst David Steinberg reiterated a Buy rating and $109 price target on Pacira Pharmaceuticals (NASDAQ: PCRX) following meetings with management.

Steinberg commented, "Pacira remains one of the rare “hyper growth” stories in life sciences – with stellar execution leading to Exparel annualizing at $180M (just 1.6% share) after 9 quarters. Mgt noted rapid growth in all targeted segments with orthopedics standing out. A relevant question is: what multiple of future sales/earnings will investors pay for Exparel’s rapid trajectory? Post a day of meetings, several sources of meaningful upside appear to be in the offing."

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $101.85 yesterday.

You May Also Be Interested In

• Benchmark on Take-Two's (TTWO) GTV 6 Release: 'we anticipate that the game will not be released within the fiscal year and expect it to launch in fiscal 2026 instead'
• Synovus Financial (SNV) PT Lowered to $42 at Piper Sandler
• Super Micro Computer (SMCI) Falls 6%